Enoxamed Study in the Treatment of Acute Coronary Syndromes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-06-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Because of their anti-Xa and ease of administration activity, the Low molecular weight heparin represent an attractive alternative to the unfractionated heparin. Several clinical trials have demonstrated that Low molecular weight heparin was more effective than Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the most studied. Its use is recommended.

Demonstrate that Enoxamed® is comparable to that of Lovenox® in the anti-Xa activity action.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enoxaparin Bioequivalence Study in Acute Coronary Syndrome Patients

NCT04552067

Acute Coronary Syndrome

COMPLETED PHASE1

Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

NCT01687491

Acute Coronary Syndrome Factor X

COMPLETED PHASE4

Enoxaparin in Acute Venous Thromboembolic Disease

NCT00265993

Venous Thrombosis

COMPLETED PHASE4

Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

NCT01729559

Venous Thromboembolic Disease Deep Vein Thrombosis Pulmonary Embolism

COMPLETED PHASE4

Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)

NCT02744833

Deep Venous Thrombosis

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Single-center randomized controlled trial, single-blind, including patient with an acute coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was done on two groups ; ENOXAMED® group : In this case the patient receives an injection of enoxaparin ( ENOXAMED® ; Unimed Laboratories) intravenously. Curative dose (100 IU/10 kg).

Control group ( LOVENOX ® ) In this case the patient receives LOVENOX intravenous injection curative dose of 100 kg IU/10 .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LOVENOX

patients are given a curative dose of Enoxaparin (LOVENOX)

Group Type OTHER

LOVENOX

Intervention Type DRUG

LMWH

ENOXAMED

patients are given a curative dose of Enoxaparin (ENOXAMED)

Group Type ACTIVE_COMPARATOR

ENOXAMED

Intervention Type DRUG

LMWH

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LOVENOX

LMWH

Intervention Type DRUG

ENOXAMED

LMWH

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age over 18 year old
* With an acute coronary syndrome confirmed

Exclusion Criteria

* Age less than 18 years
* Persistent ST- segment elevation
* Contre indication of enoxaparin and heparin in general.
* Patient participating in another study,
* Pregnant or nursing women
* patients taking an anticoagulant in the last three months,
* Patients with coagulopathy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No